



RETATRUTIDE (RETA)

TRIPLE RECEPTOR AGONIST ★ RESEARCH COMPOUND

AVAILABLE RESEARCH SIZES

10 MG | 20 MG | 30 MG | 40 MG



WHAT IS RETATRUTIDE?

Retatrutide (LY3437943) is an investigational peptide being developed as a triple hormone receptor agonist, activating:

GIP ★ GLP-1 ★ GLUCAGON

This multi-receptor mechanism is being investigated across metabolic and cardiometabolic research.



CURRENT RESEARCH AREAS

Clinical programs are evaluating retatrutide in areas including obesity/overweight, type 2 diabetes, cardiovascular and renal outcomes, obstructive sleep apnea, osteoarthritis-related outcomes, and metabolic dysfunction-associated steatotic liver disease.



RESEARCH HIGHLIGHT

In Lilly's 2026 Phase 3 TRIUMPH-1 trial, the 12 mg study arm reported an average **28.3%** body-weight **reduction** at 80 weeks. Retatrutide remains investigational while additional clinical development and regulatory review continue.

Source: Lilly Investor Relations – May 2026 Press Release (TRIUMPH-1 Trial)



PREMIUM RESEARCH QUALITY

Rigorous standards for purity and consistency.



ADVANCED RESEARCH COMPOUND

Investigational peptide for laboratory research only.



BACKED BY SCIENCE

Developed based on cutting-edge metabolic research and clinical data.



MADE IN THE USA

Proudly synthesized and quality tested in the USA.

RESEARCH USE ONLY ★ NOT FOR HUMAN USE

NOT FDA-APPROVED. NO CLAIMS ARE MADE REGARDING THE SAFETY OR EFFICACY OF FREEDOM PEPTIDES RESEARCH PRODUCTS FOR DIAGNOSING, TREATING, CURING, OR PREVENTING ANY DISEASE.

